Meet Our Partners
We secure partners who are working towards our mutual goal of finding a treatment or cure for hypoPARAthyroidism. We also partner with organizations that can help us educate both patients and physicians about our disease. Finally, we partner with organizations that can help us help patients with navigating insurance, disability, and other treatment needs.
Calcilytix Therapeutics is a clinical-stage biopharmaceutical company based in California, USA. We are an affiliate of BridgeBio Pharma, whose goal is to create life-altering medicines that target well-characterized genetic diseases at their source.
Calcilytix is investigating Encaleret as a potential treatment for ADH1 (autosomal dominant hypocalcemia type 1), a genetic cause of hypoPARAthyroidism. Encaleret is an investigational, orally-administered small molecule designed to specifically inhibit the calcium-sensing receptor, with the goal of normalizing serum calcium and lowering urine calcium. Encaleret is not yet approved by the FDA or any other regulatory authority to treat ADH1.
Together with physicians and the community, the Calcilytix team aims to develop an effective treatment option for people living with ADH1, the most common genetic form of isolated hypoPARA.
Ascendis Pharma is applying its innovative technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science, and passion, we use our TransCon® technology platform to create new and potentially best-in-class therapies.
Ascendis Pharma currently has three independent endocrinology rare disease product candidates in clinical development and is also advancing programs in Oncology and Ophthalmology. Ascendis is headquartered in Copenhagen, Denmark, and has additional offices in Heidelberg, Munich, and Berlin in Germany; Palo Alto and Redwood City, California; and Princeton, New Jersey in the United States.
Visit LivingHypoPara.com to learn more about hypoPARAthyroidism and to gain access to our library of lifestyle tips and wellness resources.
We are building and advancing a portfolio of innovative therapies through global approval by establishing strong ties and collaborations with endocrinologists, the medical community at large and patient advocacy organizations worldwide.
Our goal is to provide physicians with new therapeutic strategies to improve the lives of their patients with rare endocrine and related diseases. Currently, our development pipeline includes two therapeutic peptide programs: eneboparatide for the treatment of hypoPARAthyroidism and AZP-3813 for the treatment of acromegaly. We also continuously look for external innovation in rare endocrine and related diseases.
Our global management team is composed of a highly dedicated group of senior executives with proven drug development, registration and commercialization, and achievements in peptide therapeutics, as well as thorough knowledge of rare endocrine and related disease.
We are supported by an impressive board of directors and strong international syndicate of investors, as well as a robust IP portfolio and key academic collaborations.
MBX Biosciences is pioneering Precision Endocrine Peptide™ (PEP™) therapeutics to help people with endocrine disorders live fuller and healthier lives. Our mission is to restore health, simplify management and enable greater access for patients with endocrine diseases. The company’s lead product candidate for the treatment of hypoPARAthyroidism is currently in development and is designed to restore PTH physiology and correct the mineral imbalances to alleviate symptoms of the disorder. MBX is based in Carmel, Indiana. To learn more, please visit the company website at www.mbxbio.com and follow on LinkedIn and Twitter.
Takeda Pharmaceutical Company
Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Our passion and pursuit of potentially life-changing treatments for patients are deeply rooted in over 240 years of distinguished history in Japan.
Our corporate philosophy tells the story of Takeda — who we are, what we do, how we do it, and why it matters. It reminds us how together, we can achieve “better health for people, brighter future for the world”.
We connect to our history and Japanese heritage through everything we do today, to bring our purpose, values, vision, and imperatives to life.